Login
Israel-Hamas Conflict
Memorial Day
Cannes Film Festival
Baseball
Social Media
World Cup
Premier League
Motorsports
Champions League
Sanctions
Disney
Wrestling
US Politics
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Breakthrough: New Columvi 2-Year Data Reveals 40% Survival Advantage in Advanced Lymphoma Patients

Summary by stocktitan.net
Latest clinical data shows 89% survival rate in responding patients. Columvi combination therapy demonstrates superior efficacy in DLBCL treatment. See full results.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
targetedonc.comtargetedonc.com

Acalabrutinib Gains Landmark EU Approval in First-Line MCL

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients with mantle cell lymphoma.

Read Full Article
stocktitan.netstocktitan.net

Breakthrough: New Columvi 2-Year Data Reveals 40% Survival Advantage in Advanced Lymphoma Patients

Latest clinical data shows 89% survival rate in responding patients. Columvi combination therapy demonstrates superior efficacy in DLBCL treatment. See full results.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Friday, May 23, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal